Tiziana Life Sciences (NASDAQ:TLSA – Get Free Report) and CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of recent ratings and price targets for Tiziana Life Sciences and CNS Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tiziana Life Sciences | 1 | 1 | 0 | 0 | 1.50 |
| CNS Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 294.48%. Given CNS Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Tiziana Life Sciences.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tiziana Life Sciences | N/A | N/A | -$18.43 million | N/A | N/A |
| CNS Pharmaceuticals | N/A | N/A | -$15.85 million | ($29.63) | -0.17 |
Profitability
This table compares Tiziana Life Sciences and CNS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tiziana Life Sciences | N/A | N/A | N/A |
| CNS Pharmaceuticals | N/A | -238.68% | -166.30% |
Insider and Institutional Ownership
14.0% of CNS Pharmaceuticals shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Tiziana Life Sciences has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 3.06, suggesting that its stock price is 206% more volatile than the S&P 500.
Summary
CNS Pharmaceuticals beats Tiziana Life Sciences on 6 of the 9 factors compared between the two stocks.
About Tiziana Life Sciences
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
